TGD001 Treatment in Thrombotic Microangiopathies

Starting soon · Phase 1/Phase 2

Conditions studied: Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia

In brief

This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.

Key facts

Study ID

NCT07459114

Run by

TargED Biopharmaceuticals B.V.

People needed

70

Starts

2026-05-31

Expected to finish

2028-08-30

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.